Cancer discovery news

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time patients wait.

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major clinical trial show.

Scientists have developed a machine learning tool that can predict how an aggressive type of breast cancer will respond to treatment, and when it will return.

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP inhibitor drug, olaparib, according to new research published in the journal Cancer Cell.

Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options for cancer patients.

Researchers have identified a key weakness in acute myeloid leukaemia, offering a promising new strategy to delay the progression of this aggressive blood cancer. The discovery focuses on disrupting the function of a certain protein complex that cancer cells, including leukaemia cells, rely on to maintain their abnormal growth.

A three-drug combination for aggressive advanced breast cancer doubles the length of time before the cancer progresses, compared with a drug combination currently available on the NHS, new research has shown.

A new imaging technique could mean patients with aggressive glioblastomas benefit from cutting edge immunotherapy treatments, according to researchers.

A pioneering research study which will allow brain cancer patients to access drugs that are precisely targeted to their disease and swap to different treatments if needed, has launched in the UK.

A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ovarian cancer that rarely responds to chemotherapy or hormone therapy.

People with intermediate risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.